-
Something wrong with this record ?
Targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest: a statistical analysis plan
JC. Jakobsen, J. Dankiewicz, T. Lange, T. Cronberg, G. Lilja, H. Levin, J. Bělohlávek, C. Callaway, A. Cariou, D. Erlinge, J. Hovdenes, M. Joannidis, P. Nordberg, M. Oddo, P. Pelosi, H. Kirkegaard, G. Eastwood, C. Rylander, M. Saxena, C. Storm,...
Language English Country Great Britain
Document type Journal Article, Multicenter Study, Randomized Controlled Trial
NLK
BioMedCentral
from 2000-04-01
BioMedCentral Open Access
from 2006
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2000-04-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2009-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-04-01
Health & Medicine (ProQuest)
from 2000-04-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
Springer Nature OA/Free Journals
from 2000-04-01
- MeSH
- Fever MeSH
- Hypothermia * MeSH
- Cardiopulmonary Resuscitation * MeSH
- Humans MeSH
- Body Temperature MeSH
- Hypothermia, Induced * adverse effects MeSH
- Treatment Outcome MeSH
- Out-of-Hospital Cardiac Arrest * diagnosis therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: To date, targeted temperature management (TTM) is the only neuroprotective intervention after resuscitation from cardiac arrest that is recommended by guidelines. The evidence on the effects of TTM is unclear. METHODS/DESIGN: The Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM2) trial is an international, multicentre, parallel group, investigator-initiated, randomised, superiority trial in which TTM with a target temperature of 33 °C after cardiac arrest will be compared with a strategy to maintain normothermia and active treatment of fever (≥ 37.8 °C). Prognosticators, outcome assessors, the steering group, the trial coordinating team, and trial statisticians will be blinded to treatment allocation. The primary outcome will be all-cause mortality at 180 days after randomisation. We estimate a 55% mortality in the targeted normothermia group. To detect an absolute risk reduction of 7.5% with an alpha of 0.05 and 90% power, 1900 participants will be enrolled. The secondary neurological outcome will be poor functional outcome (modified Rankin scale 4-6) at 180 days after cardiac arrest. In this paper, a detailed statistical analysis plan is presented, including a comprehensive description of the statistical analyses, handling of missing data, and assessments of underlying statistical assumptions. Final analyses will be conducted independently by two qualified statisticians following the present plan. DISCUSSION: This SAP, which was prepared before completion of enrolment, should increase the validity of the TTM trial by mitigation of analysis-bias.
Adult Critical Care University Hospital of Wales Cardiff UK
Australian and New Zealand Intensive Care Research Centre Monash University Melbourne Australia
Clinical Studies Sweden Skåne University Hospital Lund Sweden
Department of Anesthesia and Intensive Care Oslo University Hospital Rikshospitalet Oslo Norway
Department of Cardiology Holbæk Hospital Holbæk Denmark
Department of Clinical Sciences Cardiology Lund University Skåne University Hospital Lund Sweden
Department of Clinical Sciences Neurology Lund University Skåne University Hospital Lund Sweden
Department of Critical Care Alfred Hospital Melbourne Australia
Department of Emergency Medicine University of Pittsburgh Pittsburgh PA USA
Department of Intensive Care Austin Hospital Heidelberg Australia
Department of Medicine Center for Resuscitation Science Karolinska Institute Solna Sweden
Department of Surgical Sciences and Integrated Diagnostics University of Genoa Genoa Italy
Medical Intensive Care Unit Cochin University Hospital and Paris Descartes University Paris France
Medical Research Institute of New Zealand Wellington New Zealand
University Collage Dublin Clinical Research Centre St Vincent's University Hospital Dublin Ireland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020001
- 003
- CZ-PrNML
- 005
- 20210830101611.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13063-020-04654-y $2 doi
- 035 __
- $a (PubMed)33028425
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Jakobsen, Janus Christian $u Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Tagensvej 22, Copenhagen, Denmark. jcj@ctu.dk $u Department of Cardiology, Holbæk Hospital, Holbæk, Denmark. jcj@ctu.dk $u Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. jcj@ctu.dk
- 245 10
- $a Targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest: a statistical analysis plan / $c JC. Jakobsen, J. Dankiewicz, T. Lange, T. Cronberg, G. Lilja, H. Levin, J. Bělohlávek, C. Callaway, A. Cariou, D. Erlinge, J. Hovdenes, M. Joannidis, P. Nordberg, M. Oddo, P. Pelosi, H. Kirkegaard, G. Eastwood, C. Rylander, M. Saxena, C. Storm, FS. Taccone, MP. Wise, MPG. Morgan, P. Young, A. Nichol, H. Friberg, S. Ullén, N. Nielsen
- 520 9_
- $a BACKGROUND: To date, targeted temperature management (TTM) is the only neuroprotective intervention after resuscitation from cardiac arrest that is recommended by guidelines. The evidence on the effects of TTM is unclear. METHODS/DESIGN: The Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM2) trial is an international, multicentre, parallel group, investigator-initiated, randomised, superiority trial in which TTM with a target temperature of 33 °C after cardiac arrest will be compared with a strategy to maintain normothermia and active treatment of fever (≥ 37.8 °C). Prognosticators, outcome assessors, the steering group, the trial coordinating team, and trial statisticians will be blinded to treatment allocation. The primary outcome will be all-cause mortality at 180 days after randomisation. We estimate a 55% mortality in the targeted normothermia group. To detect an absolute risk reduction of 7.5% with an alpha of 0.05 and 90% power, 1900 participants will be enrolled. The secondary neurological outcome will be poor functional outcome (modified Rankin scale 4-6) at 180 days after cardiac arrest. In this paper, a detailed statistical analysis plan is presented, including a comprehensive description of the statistical analyses, handling of missing data, and assessments of underlying statistical assumptions. Final analyses will be conducted independently by two qualified statisticians following the present plan. DISCUSSION: This SAP, which was prepared before completion of enrolment, should increase the validity of the TTM trial by mitigation of analysis-bias.
- 650 _2
- $a tělesná teplota $7 D001831
- 650 12
- $a kardiopulmonální resuscitace $7 D016887
- 650 _2
- $a horečka $7 D005334
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hypotermie $7 D007035
- 650 12
- $a terapeutická hypotermie $x škodlivé účinky $7 D007036
- 650 12
- $a zástava srdce mimo nemocnici $x diagnóza $x terapie $7 D058687
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Dankiewicz, Josef $u Department of Clinical Sciences, Cardiology, Lund University, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Lange, Theis $u Section of Biostatistics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Cronberg, Tobias $u Department of Clinical Sciences, Neurology, Lund University, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Lilja, Gisela $u Department of Clinical Sciences, Neurology, Lund University, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Levin, Helena $u Department of Clinical Sciences, Research and Education, Lund University, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Bělohlávek, Jan $u 2nd Department of Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Callaway, Clifton $u Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA, USA
- 700 1_
- $a Cariou, Alain $u Medical Intensive Care Unit, Cochin University Hospital (APHP) and Paris Descartes University, Paris, France
- 700 1_
- $a Erlinge, David $u Department of Clinical Sciences, Cardiology, Lund University, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Hovdenes, Jan $u Department of Anesthesia and Intensive Care, Oslo University Hospital, Rikshospitalet, Oslo, Norway
- 700 1_
- $a Joannidis, Michael $u Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Nordberg, Per $u Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden
- 700 1_
- $a Oddo, Mauro $u Department of Intensive Care Medicine, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) - University Hospital, University of Lausanne, Lausanne, Switzerland
- 700 1_
- $a Pelosi, Paolo $u Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy $u San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, University of Genoa, Genoa, Italy
- 700 1_
- $a Kirkegaard, Hans $u Research Center for Emergency Medicine, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus N, Denmark
- 700 1_
- $a Eastwood, Glenn $u Department of Intensive Care, Austin Hospital, Heidelberg, Australia
- 700 1_
- $a Rylander, Christian $u Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 700 1_
- $a Saxena, Manoj $u Bankstown Hospital Clinical School and The George Institute for Global Health, University of New South Wales, Kensington, Australia
- 700 1_
- $a Storm, Christian $u Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany $u Division of Neuroscience Critical Care, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 700 1_
- $a Taccone, Fabio Silvio $u Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
- 700 1_
- $a Wise, Matthew P $u Adult Critical Care, University Hospital of Wales, Cardiff, UK
- 700 1_
- $a Morgan, Matt P G $u Adult Critical Care, University Hospital of Wales, Cardiff, UK
- 700 1_
- $a Young, Paul $u Medical Research Institute of New Zealand, Wellington, New Zealand
- 700 1_
- $a Nichol, Alistair $u University Collage Dublin-Clinical Research Centre, St Vincent's University Hospital, Dublin, Ireland $u Australian and New Zealand Intensive Care-Research Centre, Monash University, Melbourne, Australia $u Department of Critical Care, Alfred Hospital, Melbourne, Australia
- 700 1_
- $a Friberg, Hans $u Department of Clinical Sciences, Anesthesia & Intensive Care, Lund University, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Ullén, Susann $u Clinical Studies Sweden, Skåne University Hospital, Lund, Sweden
- 700 1_
- $a Nielsen, Niklas $u Department of Clinical Sciences Lund, Anesthesia & Intensive Care, Lund University, Helsingborg Hospital, Lund, Sweden
- 773 0_
- $w MED00163187 $t Trials $x 1745-6215 $g Roč. 21, č. 1 (2020), s. 831
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33028425 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101611 $b ABA008
- 999 __
- $a ok $b bmc $g 1690734 $s 1140447
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 21 $c 1 $d 831 $e 20201007 $i 1745-6215 $m Trials $n Trials $x MED00163187
- LZP __
- $a Pubmed-20210728